GlobalData on MSN3d
23andMe weighing up sale of the company as cash runs dry
Me is considering a sale of the company as it weighs up strategic options, capping a torrid year for the genetic testing ...
23andMe Considers Sale as Cash Runs Low
The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.
23andMe Launches New Genetic Report on Osteoporosis
SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help ...
newsbytesapp.com2d
23andMe considers sale amid financial struggles and leadership turmoil
By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...
23andMe Board Explores Strategic Alternatives Amid Restructuring
23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...
Business Insider21d
What went wrong for 23andMe
23andMe CEO Anne Wojcicki sounded optimistic about the company's future during an earnings call in February last year. She said the biotech company, which offers direct-to-consumer genetic testing ...
BioPharma Dive1d
23andMe considers a sale as cash runs low
The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...